PH 3/4 GLASSIA SAFETY, IMMUNOGENICITY, AND BRONCHOALVEOLAR LAVAGE STUDY



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:2/17/2019
Start Date:April 21, 2016
End Date:May 29, 2020
Contact:Shire Contact
Email:ClinicalTransparency@shire.com
Phone:+1 866 842 5335

Use our guide to learn which trials are right for you!

A PHASE 3/4 STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY, AND EFFECTS ON THE ALPHA1-PROTEINASE INHIBITOR (A1PI) LEVELS IN EPITHELIAL LINING FLUID FOLLOWING GLASSIA THERAPY IN A1PI-DEFICIENT SUBJECTS

The purpose of the study is 2-fold: (1) to further evaluate the safety and potential
immunogenicity of GLASSIA following IV administration via in-line filtration; and, (2) to
assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various
biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at
a dosage of 60 mg/kg Body weight (BW)/week active A1PI protein for 25 weeks in subjects with
emphysema due to congenital A1PI deficiency.


Inclusion Criteria:

1. Male or female participants meeting the following age criteria:

1. For participants who will undergo bronchoscopy/ bronchoalveolar lavage (BAL)
procedures: 18 to 75 years of age at the time of screening.

2. For participants who will be waived from undergoing bronchoscopy/BAL procedures:
18 years of age or older at the time of screening.

2. Documented Alpha1-Proteinase Inhibitor (A1PI) genotype of Pi*Z/Z, Pi*Z/Null,
Pi*Malton/Z, Pi*Null/Null, or other "at-risk" allelic combinations such as SZ
(excluding MS and MZ) and an endogenous A1PI plasma levels of ≤11 μM.

3. Screening levels of endogenous plasma (antigenic) A1PI of ≤11 μM may be collected at
any time during the screening period for treatment-naïve participants, or following a
4 week minimum wash-out from previous augmentation therapy in treatment-experienced
participants.

4. Participants must have at least one of the following: clinical diagnosis of emphysema,
evidence of emphysema on computerized tomography (CT) scan of the chest, and/or
evidence of airway obstruction which is not completely reversed with bronchodilator
treatment at the time of screening.

5. If the participant is being treated with any respiratory medications including inhaled
bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose
systemic corticosteroids (prednisone ≤10 mg/day or its equivalent), the doses of the
participant's medications have remained unchanged for at least 14 days prior to
screening.

6. The participant is a nonsmoker or has ceased smoking for a minimum of 13 weeks prior
to screening (serum cotinine level at screening within normal range of a nonsmoker)
and agrees to refrain from smoking throughout the course of the study. Participants
with a positive cotinine test due to nicotine replacement therapy (eg, patches,
chewing gum), vapor cigarettes, or snuff are eligible.

7. If female of childbearing potential, the participant presents with a negative
pregnancy test at screening and agrees to employ adequate birth control measures for
the duration of the study.

8. The participant is willing and able to comply with the requirements of the protocol.

9. The participant must have pulmonary function at the time of screening meeting both of
the following:

1. Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥50% of
predicted.

2. If FEV1 is >80% predicted, then FEV1/forced vital capacity (FVC) must be <0.7.
*Note: Inclusion criterion #1a and #9a are not applicable to participants who are
not required to undergo the bronchoscopy/BAL procedures.

Exclusion Criteria:

1. The participant is experiencing or has a history of clinically significant pulmonary
disease (other than chronic obstructive pulmonary disease (COPD), emphysema, chronic
bronchitis, mild bronchiectasis, and stable asthma).

2. The participant is experiencing or has a history of chronic severe cor pulmonale
(resting mean pulmonary artery pressure ≥40 millimeter(s) of mercury (mm Hg)).

3. The participant routinely produces more than 1 tablespoon of sputum per day.

4. The participant has a history of frequent pulmonary exacerbations (greater than 2
moderate or severe exacerbations within 52 weeks prior to screening.

5. The participant is experiencing a pulmonary exacerbation at the time of screening
(participant may be re-screened 4 weeks after the clinical resolution of an
exacerbation).

6. The participant has clinically significant abnormalities (other than emphysema,
chronic bronchitis, or mild bronchiectasis) detected on chest X-ray or CT scan at the
time of screening. (Past records obtained within 52 weeks prior to screening may be
used, if available.)

7. The participant has clinically significant abnormalities detected on a 12-lead
electrocardiogram (ECG) performed at the time of screening. (Past records obtained
within 26 weeks prior to screening may be used, if available.)

8. The participant has clinically significant congestive heart failure with New York
Heart Association (NYHA) Class III/IV symptoms.

9. The participant is experiencing an active malignancy or has a history of malignancy
within 5 years prior to screening, with the exception of the following: adequately
treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the
cervix, or stable prostate cancer not requiring treatment.

10. The participant has a history of lung or other organ transplant, is currently on a
transplant list, or has undergone major lung surgery.

11. The participant is receiving long-term around-the-clock oxygen supplementation. (The
following are allowed: short-term use of oxygen supplementation [eg, for the
management of acute COPD exacerbation], oxygen supplementation required during night
time only, and supplemental oxygen (O2) with continuous positive airway pressure
[CPAP] or bi-level positive airway pressure [BiPAP]).

12. Known history of hypersensitivity following infusions of human blood or blood
components.

13. Immunoglobulin A (IgA) deficiency (<8 mg/dL at screening).

14. Abnormal clinical laboratory results obtained at the time of screening meeting any of
the following criteria:

1. Serum alanine aminotransferase (ALT) >3.0 times upper limit of normal (ULN)

2. Serum total bilirubin >2.0 times ULN

3. >2+proteinuria on urine dipstick analysis

4. Serum creatinine >2.0 times ULN

5. Absolute neutrophil count (ANC) <1500 cells/mm^3

6. Hemoglobin (Hgb) <9.0 g/dL

7. Platelet count <100,000/mm^3

15. Ongoing active infection with hepatitis A virus (HAV), hepatitis B virus (HBV),
hepatitis C virus (HCV), or human immunodeficiency virus (HIV) Type 1 or 2 infection
at the time of screening.

16. The participant has any clinically significant medical, psychiatric, or cognitive
illness, or any other uncontrolled medical condition (eg, unstable angina, transient
ischemic attack) that, in the opinion of the investigator, would impede the
participant's ability to comply with the study procedures, pose increased risk to the
participant's safety, or confound the interpretation of study results.

17. The participant has participated in another clinical study involving an
investigational product or investigational device within 30 days prior to enrollment
or is scheduled to participate in another clinical study involving an investigational
product or device during the course of this study.

18. The participant is a family member or employee of the investigator.

19. If female, the participant is nursing at the time of screening.

20. The participant has contraindication(s) to bronchoscopy such as recent myocardial
infarction, unstable angina, other cardiopulmonary instability, tracheal obstruction
or stenosis, moderate to severe hypoxemia or any degree of hypercapnia, unstable
asthma, Stage 4 or 5 chronic kidney disease, pulmonary hypertension, severe
hemorrhagic diathesis, and cervical C1/C2 arthritis.

21. The participant has had lung surgery which may interfere with bronchoscopy.

22. Known history of allergic/hypersensitivity reactions to medications used during and
for perioperative care associated with the bronchoscopy/BAL procedures, such as local
anesthetics, sedatives, pain control medications.

23. The participant is receiving or requires long-term (>4 weeks) immunosuppressive
therapy, such as systemic corticosteroids at doses greater than 10 mg/day of
prednisone (or its equivalent), mycophenolate mofetil, azathioprine, cyclophosphamide,
and rituximab.

24. If a participant is receiving anticoagulant or anti-platelet therapy (such as warfarin
and clopidogrel), the participant is unwilling to or unable to safely discontinue
anticoagulant or anti-platelet therapy within 7 days prior to until at least 24 hours
after the BAL procedures. An exception is low-dose aspirin alone which is allowed.

- Note: Exclusion criteria #20, #21, #22, #23, and #24 are not applicable to
participants who are not required to undergo the bronchoscopy/BAL procedures.
We found this trial at
20
sites
Tyler, Texas 75708
Principal Investigator: James Stocks, MD
Phone: 903-877-5518
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
Principal Investigator: Michael Campos, MD
Phone: 305-243-2568
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
(813) 844-7000
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Charleston, South Carolina 29425
Principal Investigator: Charlton Strange, MD
Phone: 843-792-8438
?
mi
from
Charleston, SC
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
Principal Investigator: Douglas Hogarth, MD
Phone: 773-702-1012
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Franklin, Tennessee 37064
Principal Investigator: Aaron Milstone, MD
Phone: 615-610-5592
?
mi
from
Franklin, TN
Click here to add this to my saved trials
Hannibal, Missouri 63401
Principal Investigator: Humam Farah, MD
Phone: 573-231-3239
?
mi
from
Hannibal, MO
Click here to add this to my saved trials
Hazard, Kentucky 41701
?
mi
from
Hazard, KY
Click here to add this to my saved trials
800 Commissioners Road East
London, Ontario N6A 5W9
Principal Investigator: David McCormack, MD
Phone: 519-685-8500
?
mi
from
London,
Click here to add this to my saved trials
757 Westwood Plaza
Los Angeles, California 90024
(310) 825-9111
Principal Investigator: Igor Barjaktarevic, MD
Phone: 310-206-0396
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90048
Principal Investigator: Jeremy Falk, MD
Phone: 310-423-4765
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19140
Principal Investigator: Friedrich Kueppers, MD
Phone: 215-707-4679
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
350 W Thomas Rd
Phoenix, Arizona 85013
(602) 406-3000
St. Joseph's Hospital and Medical Center St. Joseph's is a nationally recognized center for quality...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Brian Morrissey, MD
Phone: 916-703-4093
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Tamarac, Florida 33321
Principal Investigator: Alvaro Murcia, MD
Phone: 954-537-2100
?
mi
from
Tamarac, FL
Click here to add this to my saved trials
The Woodlands, Texas 77005
Principal Investigator: Ather Siddiqi, MD
Phone: 713-703-2398
?
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Towson, Maryland 21204
Principal Investigator: Linda Barr, MD
Phone: 410-494-1662
?
mi
from
Towson, MD
Click here to add this to my saved trials
Tucson, Arizona 85724
Principal Investigator: Tony Hodges, MD
Phone: 844-242-4664
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Weston, Florida 33331
Principal Investigator: Franck Rahaghi, MD
Phone: 954-659-6409
?
mi
from
Weston, FL
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
Principal Investigator: Barry Sigal, MD
Phone: 336-659-8414
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials